SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	14.50 kr	-0.28%	311,099
11/06/26	14.54 kr	+5.36%	459,861
10/06/26	13.80 kr	-3.90%	423,644
09/06/26	14.36 kr	+4.82%	384,126
08/06/26	13.70 kr	+1.63%	290,712

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 20:00:00 12/06/2026 +04			5-day change	1st Jan Change
14.50 ^SEK	-0.28%		+6.46%	-35.84%

07:39pm	Peace Optimism Lifts Stockholm Exchange: Duni Falls on Profit Warning	FW
07:09pm	Synact secures US patent for resomelagon: exclusivity extended to 2044	FW

Market Cap	772M 82.1M 70.91M 65.35M 61.17M 115M 7.8B 116M 301M 3.8B 308M 302M 13.15B	P/E Ratio 2026 *	-9.73x	P/E Ratio 2027 *	-19.1x
Enterprise Value	754M 80.24M 69.31M 63.87M 59.78M 112M 7.63B 114M 294M 3.71B 301M 295M 12.85B	EV / Sales 2026 *	5.44x	EV / Sales 2027 *	37.7x
Free-Float	70.28%	Yield 2026 *	-	Yield 2027 *	-

07:39pm	Peace Optimism Lifts Stockholm Exchange: Duni Falls on Profit Warning	FW
07:09pm	Synact secures US patent for resomelagon: exclusivity extended to 2044	FW
07:06pm	Synact Pharma Secures U.S. Patent	FW
05-27	SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-27	Synact losses widen as expected; ADVANCE topline data anticipated in June	FW
05-27	Calendar Wednesday May 27	FW
05-26	Major Synact Pharma shareholder order placed in error	FW
05-06	Synact Pharma doses final patient in ADVANCE study	FW
05-06	SynAct Pharma AB Completes Dosing for Last Patient in Phase 2B Advance Study	CI
03-26	Synact Pharma doses first patients in dengue study	FW
03-26	SynAct Pharma AB Doses First Patients in the Phase 2 RESOVIR-2 Study with Resomelagon	CI
03-18	Synact Pharma to attend and present at BIO-Europe Spring	FW
03-11	SynAct Pharma AB - Analyst/Investor Day

03-04	Edison Raises Valuation of Synact Pharma - Commissioned Analysis	FW
02-09	Redeye Raises Target Price for Synact Pharma to 31 Kronor (26)	FW
31/10/25	Redeye Raises Target Price for Synact Pharma to 26 Kronor (25)	FW
28/10/25	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 Per Share	FW
28/10/25	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 per Share	FW

SynAct Pharma AB Stock

Stocks

SYNACT

SE0008241491

Pharmaceuticals

Valuation: SynAct Pharma AB

Chart: SynAct Pharma AB

Latest news : SynAct Pharma AB

Last Transcript: SynAct Pharma AB

Analysts' recommendations: SynAct Pharma AB

Press Releases: SynAct Pharma AB

Quotes and Performance

Course Extremes

Managers and Directors: SynAct Pharma AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07:06pm	SynAct obtains key US patent for resomelagon securing exclusivity until 2044	AQ
06-11	Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ)	AQ
05-27	SynAct Pharma publishes Q1 2026 interim results	AQ
05-26	Synact Pharma large shareholder trading update	AQ
05-19	SynAct Pharma to present at the BioStock Global Forum 2026 on May 21	AQ

1 day	-0.41%
1 week	+6.46%
Current month	-16.76%
1 month	-2.42%
3 months	-20.07%
6 months	-31.92%
Current year	-35.84%

1 week	12.9	15.32
1 month	12.82	18.2
Current year	12.82	24.4
1 year	12.82	25.3
3 years	4.98	124.6
5 years	4.98	146
10 years	4.75	146

Manager	Title	Age	Since
Jeppe Øvlesen CEO	Chief Executive Officer	64	01/01/2014
Ann Kristin Led DFI	Director of Finance/CFO	-	01/03/2026
Kirsten Harting CTO	Chief Tech/Sci/R&D Officer	-	15/02/2024

Director	Title	Age	Since
Jeppe Øvlesen BRD	Director/Board Member	64	20/03/2024
Anders Kronborg CHM	Chairman	62	20/03/2024
Sten Scheibye BRD	Director/Board Member	74	20/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-10	Anders Kronborg	Buy	Chairman	2,750	0.0052%
03-09	Mads Bjerregaard	Buy	Executive/Senior Manager	1,500	0.0028%
03-09	Quantass ApS	Buy	Company	7,900	0.0148%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNACT PHARMA AB	-0.28%	+6.46%	-14.71%	-80.00%	81.09M
ELI LILLY AND COMPANY	-2.41%	+0.14%	+39.53%	+154.43%	1,035B
JOHNSON & JOHNSON	+1.07%	+3.48%	+53.75%	+50.64%	574B
ABBVIE INC.	+1.32%	+0.22%	+18.35%	+65.35%	397B
ROCHE HOLDING AG	+0.58%	+0.77%	+21.19%	+15.95%	324B
ASTRAZENECA PLC	-0.85%	-0.68%	+23.44%	+14.94%	281B
NOVARTIS AG	+0.44%	+5.39%	+25.86%	+35.39%	278B
NOVO NORDISK A/S	+1.66%	+1.20%	-44.41%	-47.37%	193B
AMGEN INC.	+0.32%	+1.61%	+19.48%	+63.42%	191B
GILEAD SCIENCES, INC.	-0.22%	-2.76%	+12.08%	+61.30%	156B
Average	+0.19%	+2.19%	+15.46%	+33.40%	343B
Weighted average by Cap.	-0.23%	+2.39%	+28.20%	+71.91%

	2026 *	2027 *
Net sales	139M 14.76M 12.75M 11.75M 11M 20.61M 1.4B 20.93M 54.1M 683M 55.41M 54.23M 2.37B	21.15M 2.25M 1.94M 1.79M 1.68M 3.14M 214M 3.19M 8.25M 104M 8.45M 8.27M 361M
Net income	52.18M 5.55M 4.8M 4.42M 4.14M 7.75M 528M 7.87M 20.34M 257M 20.84M 20.39M 889M	-26.04M -2.77M -2.39M -2.21M -2.06M -3.87M -263M -3.93M -10.15M -128M -10.4M -10.18M -444M
Net Debt	-17.48M -1.86M -1.61M -1.48M -1.39M -2.6M -177M -2.64M -6.82M -86.05M -6.98M -6.83M -298M	24.86M 2.65M 2.28M 2.11M 1.97M 3.69M 251M 3.75M 9.69M 122M 9.93M 9.72M 424M